patent/CN-107108588-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107108588-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6e69edd7628feea8e3deab3bf7fef43
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate	2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d0541792b589cbe9c089fd83eeeebae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a905be04a156ee97527e7af747b06c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12544851bd473ab0c186943d5c45adb0
publicationDate	2017-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-107108588-A
titleOfInvention	Fused bicyclic (hetero)aromatic compounds useful in the treatment of cancer
abstract	The present invention relates to novel compounds. The compounds of the present invention are kinase inhibitors. In particular, the compounds of the invention are useful as inhibitors of Raf kinases such as B-Raf and C-Raf. The present invention also contemplates the use of the compounds for the treatment of conditions treatable by inhibition of Raf kinase, such as cancer, sarcoma, melanoma, skin cancer, hematological tumors, lymphoma, epithelial cancer and leukemia.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400065-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602512-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11504347-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766418-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11583510-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602513-B1
priorityDate	2014-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9963974-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013097224-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468137037 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466362183 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466793581 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466930254

Total number of triples: 38.